It is therefore worth discussing the therapeutic implications of DNAM-1 agonism as a therapeutic strategy in cancer whether it be as a stand-alone strategy or more appropriately in synergy with TIGIT/PD-1 blockade. This evidence concerns the gene CD226 and cancer.